These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 12697291)
21. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. Sterling J; Veinberg A; Lerner D; Goldenberg W; Levy R; Youdim M; Finberg J J Neural Transm Suppl; 1998; 52():301-5. PubMed ID: 9564630 [TBL] [Abstract][Full Text] [Related]
22. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Youdim MB Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653 [TBL] [Abstract][Full Text] [Related]
23. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. Sterling J; Herzig Y; Goren T; Finkelstein N; Lerner D; Goldenberg W; Miskolczi I; Molnar S; Rantal F; Tamas T; Toth G; Zagyva A; Zekany A; Finberg J; Lavian G; Gross A; Friedman R; Razin M; Huang W; Krais B; Chorev M; Youdim MB; Weinstock M J Med Chem; 2002 Nov; 45(24):5260-79. PubMed ID: 12431053 [TBL] [Abstract][Full Text] [Related]
24. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. Bar-Am O; Amit T; Youdim MB J Neurochem; 2007 Oct; 103(2):500-8. PubMed ID: 17635668 [TBL] [Abstract][Full Text] [Related]
25. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Youdim MB; Amit T; Falach-Yogev M; Bar Am O; Maruyama W; Naoi M Biochem Pharmacol; 2003 Oct; 66(8):1635-41. PubMed ID: 14555244 [TBL] [Abstract][Full Text] [Related]
26. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. Binda C; Hubálek F; Li M; Herzig Y; Sterling J; Edmondson DE; Mattevi A J Med Chem; 2005 Dec; 48(26):8148-54. PubMed ID: 16366596 [TBL] [Abstract][Full Text] [Related]
28. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406 [TBL] [Abstract][Full Text] [Related]
29. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs. Weinreb O; Mandel S; Bar-Am O; Yogev-Falach M; Avramovich-Tirosh Y; Amit T; Youdim MB Neurotherapeutics; 2009 Jan; 6(1):163-74. PubMed ID: 19110207 [TBL] [Abstract][Full Text] [Related]
30. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Maruyama W; Youdim MB; Naoi M Ann N Y Acad Sci; 2001 Jun; 939():320-9. PubMed ID: 11462787 [TBL] [Abstract][Full Text] [Related]
31. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. Bar-Am O; Yogev-Falach M; Amit T; Sagi Y; Youdim MB J Neurochem; 2004 Jun; 89(5):1119-25. PubMed ID: 15147504 [TBL] [Abstract][Full Text] [Related]
32. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Weinstock M; Gorodetsky E; Poltyrev T; Gross A; Sagi Y; Youdim M Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):555-61. PubMed ID: 12787840 [TBL] [Abstract][Full Text] [Related]
33. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Mandel S; Weinreb O; Amit T; Youdim MB Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677 [TBL] [Abstract][Full Text] [Related]
34. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. Hubálek F; Binda C; Li M; Herzig Y; Sterling J; Youdim MB; Mattevi A; Edmondson DE J Med Chem; 2004 Mar; 47(7):1760-6. PubMed ID: 15027867 [TBL] [Abstract][Full Text] [Related]
35. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Naoi M; Maruyama W; Youdim MB; Yu P; Boulton AA Inflammopharmacology; 2003; 11(2):175-81. PubMed ID: 15035819 [TBL] [Abstract][Full Text] [Related]
36. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Jenner P; Langston JW Mov Disord; 2011 Nov; 26(13):2316-23. PubMed ID: 21953831 [TBL] [Abstract][Full Text] [Related]
37. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. Binda C; Hubálek F; Li M; Herzig Y; Sterling J; Edmondson DE; Mattevi A J Med Chem; 2004 Mar; 47(7):1767-74. PubMed ID: 15027868 [TBL] [Abstract][Full Text] [Related]
38. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006 [TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease. Bautista-Aguilera OM; Esteban G; Bolea I; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Samadi A; Soriano E; Unzeta M; Marco-Contelles J Eur J Med Chem; 2014 Mar; 75():82-95. PubMed ID: 24530494 [TBL] [Abstract][Full Text] [Related]
40. BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson׳s disease. Ledreux A; Boger HA; Hinson VK; Cantwell K; Granholm AC Brain Res; 2016 Jan; 1631():34-45. PubMed ID: 26607251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]